Loading...
Market
Will Neuralink receive approval to expand Canadian trials beyond ALS and SCI by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Health Canada announcements or Neuralink press releases
Story
Neuralink Approved for First Clinical Trial in Canada Using N1 Chip for ALS and SCI Patients
Nov 20, 2024, 07:51 PM
Neuralink has received approval from Health Canada to initiate recruitment for its first clinical trial in Canada, aimed at individuals with quadriplegia due to ALS or spinal cord injury (SCI). The trial will utilize Neuralink's N1 chip, which enables paralyzed individuals to control devices such as computers through brain-computer interface (BCI) technology. This advancement is expected to have a transformative impact on the lives of many. Interested participants can find more information and apply through Neuralink's Patient Registry.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
